Detalus Advisors, LLC Gilead Sciences, Inc. Transaction History

Detalus Advisors, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 04, 2022	SELL	$59.54 - $68.01 $13,396 - $15,302	-225 Reduced 2.97%	7,350 $453,000
Q2 2022 Jul 27, 2022	BUY	$57.72 - $65.01 $5,772 - $6,501	100 Added 1.34%	7,575 $468,000
Q1 2022 Apr 25, 2022	BUY	$57.92 - $72.58 $68,056 - $85,281	1,175 Added 18.65%	7,475 $444,000
Q4 2021 Jan 18, 2022	BUY	$64.88 - $73.64 $58,391 - $66,276	900 Added 16.67%	6,300 $457,000
Q3 2021 Oct 20, 2021	BUY	$67.69 - $73.03 $6,769 - $7,303	100 Added 1.89%	5,400 $377,000
Q2 2021 Jul 14, 2021	BUY	$63.47 - $69.35 $101,552 - $110,959	1,600 Added 43.24%	5,300 $365,000
Q1 2021 Apr 15, 2021	BUY	$60.0 - $68.46 $12,000 - $13,691	200 Added 5.71%	3,700 $239,000
Q4 2020 Jan 19, 2021	BUY	$56.65 - $64.55 $198,275 - $225,925	3,500 New	3,500 $204,000

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Detalus Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Detalus Advisors, LLC with notifications on news.